Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MOD-6031 in Healthy Volunteers
NCT02692781Phase 1Completed
- Sponsor
- OPKO Health
- Start
- Feb 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of MOD-6031 in obesity (5 cohorts), sponsored by OPKO Health. Primary endpoint: Composite safety and tolerability parameters at 30 days. Started Feb 2016; status: completed.
02
Drugs
MOD-6031
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02692781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02692781.